Newsletter | May 2, 2025

05.02.25 -- FDA RIFs Might Delay Your Review — Here Are Tips For Mitigating

SPONSOR

Multispecific molecules bring added complexity to downstream purification—think incorrect chain pairings, aggregation, fragmentation, and lower yields. Join Bioprocess Online Live as we explore how developers are addressing these challenges to achieve high purity and efficient processes. Gain insights into key considerations for downstream teams when designing purification strategies for these advanced biologics. Registration is free thanks to the support of Thermo Fisher Scientific.

FOCUS ON QUALITY/ANALYTICAL METHODS

Is It Ever Too Soon To Start Your Performance Testing Assessment?

Developing a safe and effective injectable combination product involves performing risk assessments, establishing a set of Critical Quality Attributes (CQAs), and performing design verification testing.

Optimizing DSP With Faster Timelines, Lower Costs, And Quality Processes

The biopharmaceutical industry faces growing downstream processing challenges in purifying complex biologics efficiently and at scale.

Biocompatibility Studies On CHO Cell Culture In X-Ray Irradiated Bioreactors

In cell culture, the leakage of toxic or inhibitory chemicals from single-use bioreactors has become a growing concern. Explore recommendations for leachable studies.

Antibody-Drug Conjugates – Catalysts For Chemistry

Review the complexities of developing linkers – chemical moieties which attach a drug payload to an antibody – and considerations when identifying a CRO for ADC research and development.

HCP Detection And Quantitation

Learn the ins and outs of host cell proteins (HCPs), HCP ELISA, and HCP contaminants, as well as how to improve your recombinant protein production.

QUALITY/ANALYTICAL METHODS SOLUTIONS

Bio-Expo Live February 2025: Upstream Bioprocessing - 908 Devices

Analysis Kits And Capillary Arrays - Agilent Technologies

NEW PODCAST EPISODE

Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie

On this episode of Business of Biotech, Brian Lortie, President and CEO of Uniquity Bio, shares how his "no jerk" policy shapes leadership and culture at the clinical-stage immunology startup. Host Ben Comer dives into Lortie's experience at GSK, Endo, and Onspira, and explores Uniquity’s formation, business model, and strategy with Blackstone Life Sciences backing. Listen now!

FOCUS ON REGULATORY

FDA RIFs Might Delay Your Review — Here Are Tips For Mitigating

Mounting concerns that FDA reviewers could start missing PDUFA deadlines have put many on edge. The moment calls for defensive and offensive strategies.

Regulatory Considerations For First-Time Drug Developers

Navigate the challenging path from concept to clinical reality by partnering with an experienced CDMO that can provide the regulatory, clinical, and CMC expertise needed to move your therapeutic forward and bring it closer to patients in need.

The Case For A Facility Monitoring System

Facility monitoring software with OPC UA client/server functionality makes great business sense. Learn how monitoring leads to reduced waste, improved yield, higher quality, and increased profits.

Connect With Bioprocess Online: